Genetic Technologies Ltd
Company Profile
Business description
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Contact
60-66 Hanover Street
Fitzroy
MelbourneVIC3065
AUST: +61 384127000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
60
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
stocks
Is the market still overlooking Alibaba’s AI potential?
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,185.70 | 36.60 | 0.40% |
| CAC 40 | 7,870.34 | 65.37 | 0.84% |
| DAX 40 | 24,377.50 | 191.91 | 0.79% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,177.24 | 12.01 | 0.13% |
| HKSE | 25,215.10 | 304.22 | -1.19% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 43,166.22 | 516.96 | 1.21% |
| NZX 50 Index | 12,894.91 | 60.83 | 0.47% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,911.20 | 37.40 | 0.42% |
| SSE Composite Index | 3,683.58 | 17.14 | 0.47% |